During the global COVID-19 outbreak, BioEcho developed a rapid extraction protocol that reduced the isolation of SARS-CoV-2-RNA to just a few minutes. Currently, BioEcho offers a CE-marked viral RNA/DNA extraction kit and is implementing automated solutions that will allow customers to increase their diagnostics throughput.

Danish ADCendo ApS will use the funds from a Series A investment to advance Antibody-Drug Conjugates (ADCs) entering cancer cells through endocytic receptors.

The Venture Capital Company Kurma Partners, based in Paris and Munich, appointed Jean-Francois Rivassou as new Partner.

DNA Script will receive a $5m DARPA grant as part of the agency’s Nucleic Acids On-Demand World-Wide Program to prevent the next viral pandemic.

Researchers at Novavax and from the University of Oxford reported an efficacy of 77% of their malaria vaccine, R21/Matrix-M from a Phase II trials in Burkina Faso.

GSK’s and Vir Therapeutics’ COVID-19 antibody treatment VIR-7831 has entered Phase III testing within the UK’s COVID-19 drug testing platform, AGILE

After a positive re-evaluation of J&J’s COVID-19 vaccine by the European Medicines Agency (EMA), J&J has re-started to ship 55 million doses to the EU.

Endeavour Vision has announced the closing of its Heathtech fund  Endeavour Medtech Growth II (EMG II) LP at US$375 million in capital commitments.

The Swiss biotech industry experienced a record investment in the pandemic year 2020, according to the new Swiss Biotech Report.

The European Union has exercised its option  to order 100 million additional doses of BNT162b2 bringing its orders to 600 million doses at €14.70 per shot.